SEGMENT INFORMATION - Company`S Segment, Including Segment Expenses, and A Reconciliation to Net Income (Loss) (Details) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2025	Mar. 31, 2024
Segment Reporting Information [Line Items]
Total revenues		$ 744,856	$ 413,464
Segment expenses and other segment items
Cost of sales (excluding amortization of in-licensed rights)		137,564	50,559
Selling, general and administrative- other (excluding non-cash items)		133,629	127,003
(Loss) gain on strategic investments		(90,728)	931
Interest expense		(4,503)	(4,166)
Interest income		10,190	7,093
Income tax expense		63,990	5,329
Depreciation and amortization expense		9,978	8,744
Stock-based compensation expense		41,428	40,692
Net (loss) income		(447,508)	36,119
Reconciliation of profit or loss
Adjustments and reconciling items		0	0
Net (loss) income - basic		(447,508)	36,119
Operating Segments [Member]
Segment Reporting Information [Line Items]
Total revenues		744,856	413,464
Segment expenses and other segment items
Cost of sales (excluding amortization of in-licensed rights)		137,564	50,559
Compensation and other personnel expenses		93,084	83,587
Up-front and milestone expenses		583,787	0
Manufacturing expenses		67,465	69,700
Clinical trial expenses		33,147	44,147
Facility- and technology-related expenses (excluding depreciation and amortization)		27,657	24,978
Research and development- other (excluding non-cash items)	[1]	28,471	28,848
Selling, general and administrative- other (excluding non-cash items)	[2]	51,142	48,962
Roche Collaboration Reimbursement		(28,481)	(21,658)
Other segment items	[3]	(1,909)	(2,685)
(Loss) gain on strategic investments		90,728	(931)
Interest expense		4,503	4,166
Interest income		(10,190)	(7,093)
Income tax expense		63,990	5,329
Depreciation and amortization expense		9,978	8,744
Stock-based compensation expense		41,428	40,692
Net (loss) income		(447,508)	36,119
Reconciliation of profit or loss
Net (loss) income - basic		$ (447,508)	$ 36,119

[1] Research and development-other includes professional services, pre-clinical expenses and research and other expenses.

[2] Selling, general and administrative-other includes professional services and other expenses.

[3] Other segment items included in segment net (loss) income include accretion of investment discount, net, change in fair value of derivatives and other, net, as well as the items separately presented and not defined as significant expenses below.